Abstract. To identify a possible new treatment modality for malignant pleural mesothelioma (MPM), we examined whether combination treatment consisting of pemetrexed chemotherapy and photodynamic therapy (PDT) using the photosensitizer NPe6, enhanced the antitumor effect in both in vitro and in vivo models. We also investigated preclinical treatment schedules. Four human malignant mesothelioma cell lines (MSTO-211H, H2052, H2452 and H28) were assayed using the WST assay after treatment with pemetrexed and NPe6-PDT. The treatment schedule for the combination treatment was examined using nude mice. Pemetrexed pre-treatment enhanced the lethal effect of NPe6-PDT in the four malignant mesothelioma cell lines, but NPe6-PDT followed by pemetrexed treatment did not enhance cell lethality in the in vitro assay. Pemetrexed pre-treatment did not enhance the intracellular accumulation of NPe6, which is one of the determinants of the antitumor effect of PDT. In nude mice injected with MSTO-211H cells and then treated using a combination of pemetrexed and NPe6-PDT (10 mg/kg NPe6, 10 J/cm² laser irradiation), the tumor volume decreased by 50% but subsequently increased, reaching the pre-treatment value after 14 days. Pemetrexed treatment followed by NPe6-PDT resulted in an 80% reduction in the tumor size and inhibited re-growth. NPe6-PDT followed by pemetrexed treatment resulted in a 60% reduction in tumor size but did not inhibit re-growth. NPe6-PDT induced the expression of thymidylate synthase (TS), which confers resistance to pemetrexed, and NPe6-PDT followed by pemetrexed treatment did not enhance the treatment outcome in vivo. In conclusion, combination treatment, consisting of pemetrexed followed by NPe6-PDT, should be further investigated as a new treatment modality for MPM. In the future, this combination treatment may contribute to a reduction in local recurrence and a prolonged survival period in patients with MPM.

Introduction

Malignant pleural mesothelioma (MPM) is a locally aggressive disease characterized by a poor prognosis and an increasing incidence (1‑4). MPM is difficult to detect at an early stage, and surgical and radiotherapeutic approaches are ineffective when used independently, because MPM spreads diffusely in the surrounding chest wall (5). No universally accepted treatment approach currently exists. An extrapleural pneumonectomy (ePP) with en bloc resection of the lung, pleura, ipsilateral diaphragm, and pericardium is one of the most invasive surgical procedures and is associated with a high risk of local recurrence (6,7). Recently, adjuvant radiation therapy to the ipsilateral hemithorax after ePP has been reported to result in a dramatic reduction in local relapse and the prolonged survival of patients with early-stage disease (8). Pemetrexed, a multi-target anti-folate, exhibits activity against various tumors, but especially against MPM and non-small cell lung cancer (NSCLC), for which it is routinely used (9). Pemetrexed inhibits at least three kinds of enzymes involved in folate metabolism, and in pyrimidine and purine biosynthesis: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycaminide ribonucleotide formyltransferase (10). Combination of pemetrexed and cisplatin has become the standard first-line regimen for MPM based on the results of a phase III trial showing that this combination improved survival compared with cisplatin treatment alone (11). However, the impacts of induction chemotherapy using pemetrexed and cisplatin, and of adjuvant hemithoracic radiation therapy after EPP for MPM remain controversial (12). Flores et al reported that patients who underwent a pleurectomy/decortication had a better survival outcome than those who underwent EPP (13).

Photodynamic therapy (PDT) consists of the use of a tumor-specific photosensitizer and laser irradiation to induce the production of reactive oxygen species in cancer cells (14,15). This treatment modality is used for many
cancers and is widely used as a treatment option for solid cancers (16-18). The use of PDT as a treatment for MPM has been investigated under both clinical and experimental conditions (19-21). Friedberg et al reported a phase I clinical trial of Foscan-mediated PDT and surgery in patients with MPM (20). They reported that Foscan-mediated PDT afforded the option of accomplishing tumor debulking using a lung-sparing pleurectomy/decortication, rather than EPP. A phase III randomized trial of surgery and chemotherapy with or without intra-operative PDT using the first-generation photosensitizer Photofrin, was reported in 1997 (22). The study concluded that PDT using Photofrin did not prolong patient survival or increase local MPM control. However, we recently reported that PDT using the second-generation photosensitizer NP6, has a strong antitumor effect against large tumors, which are unsuitable for treatment with Photofrin-PDT (23). NP6 has a major absorption band at 664 nm, which is longer than the Photofrin band (630 nm), and NP6-PDT can affect deeper lesions. Therefore, in an attempt to establish a new treatment modality for MPM, we examined the antitumor effect of combination therapy consisting of pemetrexed chemotherapy and NP6-PDT by comparing the antitumor effects of pemetrexed administered before or after NP6-PDT in both in vitro and in vivo models.

Materials and methods

Cell cultures. The human mesothelioma cell lines, H28, H2452, MSTO-211H, and H2052 were purchased from the American Type Culture Collection (ATCC) (Manassas, VA, USA) (24,25). These cell lines and human breast cancer MCF-7 cells transfected with human procaspase-3 cDNA (MCF-7c3 cells) were cultured in RPMI-1640 medium containing 10% fetal bovine serum (26).

Photosensitizer. NP6 (Meiji Seika Pharma Co., Ltd., Tokyo, Japan) is a second-generation water-soluble photosensitizer with a molecular weight of 799.69 and a chlorine annullus; its highest absorption peak occurs at 407 nm, while a second peak occurs at 664 nm (17,27).

Laser unit. A diode laser (Panasonic Healthcare Co., Ltd., Kanagawa, Japan) emitting continuous wave laser light at a wavelength of 664 nm was used as the light source for the excitation of NP6 (28).

Measurement of the fluorescence intensity of NP6 in the cells. MSTO-211H cells were exposed to pemetrexed at an IC50 dose of 1.2 µM for 48 h, and then were exposed to NP6 (15 µg/ml) for 4 h. The cells were washed with phosphate buffered saline (PBS). The NP6 remaining in the cells was excited at 405 nm, and the fluorescence was detected with a charged coupled device (CCD) camera system (Argus/HiSCa; Hamamatsu Photonics Co. Ltd., Shizuoka, Japan) through a multilaminate interference filter capable of selecting a fluorescence wavelength of 630 nm, as previously reported (29).

Determination of cell viability. We evaluated the growth inhibitory effects using the tetrazolium salt WST-1 assay according to the manufacturer’s instructions, as described previously (29,30). The effects of four different treatment schedules were examined. For the treatment of PDT alone, cells were seeded into 96-well microculture plates at a density of 1x10^4 cells/well and allowed to adhere to the dish overnight. NP6 was then added to the medium in increasing concentrations, followed by incubation at 37°C in the dark for 24 h. The cells were washed with PBS and the medium was replaced; the cells were then irradiated with a laser (33 mW/cm²; total energy, 10 J/cm²) and cell viability was measured 72 h later. For the treatment of PDT followed by pemetrexed, the cells were incubated with NP6 (10 µg/ml) for 24 h. Then, the cells were treated by PDT and the medium was replaced with a medium containing pemetrexed, followed by culturing for 48 h. For the treatment of pemetrexed alone, the cells were incubated with pemetrexed for 48 h. For the treatment of pemetrexed followed by PDT, the cells were incubated with pemetrexed; 24 h later, NP6 (10 µg/ml) was added. Forty-eight hours later, the cells were treated by PDT then incubated for 24 h. For each protocol, the cell viability was measured at 72 h after the start of the treatment. Independent experiments were repeated at least three times to confirm the data.

Nude mice. Five-week-old BALB/c nude mice weighing 20-30 g were obtained from the Charles River Laboratories International, Inc. (L’Aubresle, France). The animal experiments were conducted in accordance with the guidelines of the Animal Ethics Committee of Tokyo Medical University, complying with the Guidelines for the Welfare and Use of Animals in Cancer Research (31).

Protocol and therapeutic procedures. MSTO-211H cells were washed twice in Hank’s solution (Invitrogen Life Technologies, Carlsbad, CA, USA), and 10⁷ cells were injected subcutaneously into the right thigh of individual nude mice. Treatments were initiated 7 days after tumor cell implantation, when the MSTO-211H tumors were ~200 mm³ in volume. The tumor volumes were calculated using the following formula: tumor volume = L²D/2 (L, long diameter; D, short diameter) (32). For the pemetrexed followed by PDT treatment, mice were intraperitoneally injected with pemetrexed (150 mg/kg) daily on days 7-11; on day 12, mice were intravenously injected with NP6 (10 mg/kg) and irradiated with a 664-nm laser (100 J/cm²) 2 h later. The irradiation time was 16 min and 40 sec. For the PDT followed by pemetrexed treatment, mice were intravenously injected with NP6 (10 mg/kg) and 2 h later irradiated with a 664-nm laser (100 J/cm²) on day 7; on days 8-12, the mice were intraperitoneally injected with pemetrexed (150 mg/kg) daily. The progress of each tumor was measured every day until day 28, and the ratio of the tumor volume was calculated by comparing the volume with the tumor volume on day 7. All the in vivo studies were performed in accordance with the Guidelines for the Welfare and Use of Animals in Cancer Research (31).

Immunohistochemical analysis. Cells were grown on glass coverslips in 35-mm petri dishes. To analyze the expression of TS, the coverslips were removed from the petri dishes, washed with PBS, and fixed in 1% formaldehyde for 30 min.
After rinsing twice with PBS, the fixed cells were incubated in IFA buffer (PBS containing 1% bovine serum albumin, 0.1% Tween-20) for 10 min and then in IFA-containing mouse anti-TS antibody (clone 8F1; Zymed Laboratories, Inc., San Francisco, CA, USA) for 1 h at room temperature (26,30,32).

The MSTO-211H tumors in BALB/c nude mice were collected before PDT and 24 h after PDT. We performed an immunohistochemical analysis of these samples using anti-TS antibody (clone 8F1; Zymed Laboratories, Inc.).

Results

NPe6-PDT alone, but not pemetrexed alone, exerts a strong antitumor effect against human malignant mesothelioma cell lines. We examined the antitumor effects of pemetrexed on MSTO-211H, NCI-H2052, NCI-H2452, and NCI-H28 using the WST assay (Fig. 1A). The IC_{50} values of pemetrexed were 1.2 µM for MSTO-211H, 0.1 µM for NCI-H2052, 10 µM for NCI-H2452, and 8.4 µM for NCI-H28; these values were similar to those in a previous report (25). In MCF-7c3, the IC_{50} value was 5.5 µM (Fig. 1A). Unfortunately, treatment using pemetrexed alone was not sufficient to reach an LD_{90} in the NCI-H2452, and NCI-H28 cell lines, as previously reported (25). On the other hand, NPe6-PDT caused complete cell death in all four cell lines, and NPe6-PDT exerted a strong antitumor effect against MPM in vitro, with an LD_{90} being reached in all the cell lines (Fig. 1B). The IC_{50} values were 10 µg/ml of NPe6 and 10 J/cm^2, 33 mW/cm^2 of laser irradiation.
Pemetrexed enhances the lethal effects of NPe6-PDT against MPM cell lines. We examined the effects of combination therapy using pemetrexed and NPe6-PDT. First, we evaluated whether pemetrexed pre-treatment enhanced the antitumor effect of NPe6-PDT in MPM cells. MPM cells were treated with pemetrexed for 48 h and then washed with PBS three times; the cells were then incubated for 4 h with NPe6 (10 µg/ml). After incubation, the cells were irradiated with a diode laser (664 nm, 10 J/cm²), which provided the IC₅₀ dose of NPe6-PDT in MSTD-211H cells. As shown in Fig. 2A, the IC₅₀ values were 0.08 µM for the MSTD-211H cells, 0.14 µM for the H28 cells, 0.23 µM for the H2452 cells, and 0.06 µM for the H2052 cells. Thus, pemetrexed treatment followed by NPe6-PDT caused an initial decrease in...
viability, indicating that pemetrexed enhances the lethal effect of NPe6 (Fig. 2A).

**NPe6-PDT followed by pemetrexed treatment yielded no enhancement.** We next examined whether NPe6-PDT followed by pemetrexed treatment enhanced the antitumor effect. First, MPM cells were treated with NPe6-PDT using the IC_{50} conditions (NPe6, 10 µg/ml; laser irradiation, 10 J/cm^2). Then, the cells were treated with pemetrexed for 48 h. The survival curves indicated that NPe6-PDT followed by pemetrexed treatment was incapable of obtaining an IC_{50} response except in the H2052 cells, and no enhancement of the treatment effects was observed (Fig. 2B).

**Pemetrexed treatment enhanced the antitumor effect of NPe6-PDT against MPM tumors in vivo.** We examined the efficacy of combination therapy with NPe6-PDT and chemotherapeutic pemetrexed for MPM tumors. We transplanted MSTO-211H cells into nude mice as described in previous reports (33), and then treated the mice with pemetrexed for 5 days. On the sixth day of treatment, we treated the tumors with NPe6-PDT using 10 mg/kg of NPe6 and 10 J/cm^2 of laser irradiation. Fig. 3 shows that pemetrexed pre-treatment followed by NPe6-PDT enabled an 80% loss in the tumor volume and inhibited the re-growth of the tumors. Using this dosage, NPe6-PDT alone decreased the tumor volume by 50%; however, the tumor volume increased once again, reaching the pre-treatment value 10 days after PDT (Fig. 3).

We also evaluated the efficacy of NPe6-PDT followed by pemetrexed treatment, but this treatment schedule did not inhibit the re-growth of the tumor (Fig. 3). NPe6-PDT followed by pemetrexed treatment yielded no enhancement in tumor cell lethality in the in vivo experiments, similar to the results in vitro (Fig. 3).

**Pemetrexed did not stimulate the accumulation of intracellular NPe6 in MSTO-211 cells.** To examine the mechanism responsible for the enhancement in cell lethality enabled by pemetrexed pre-treatment followed by NPe6-PDT, we investigated whether pemetrexed stimulates the intracellular accumulation of NPe6 in MSTO-211 cells. MSTO-211 cells were pre-treated for 48 h with an IC_{50} dose of 1.2 µM, then exposed to NPe6 for 3 h. The resulting accumulation of NPe6 was assessed by detecting red fluorescence using fluorescent microscopy (29). No significant difference in the intracellular accumulation of NPe6 was observed between a group with pemetrexed pre-treatment and one without the pre-treatment. Thus, pemetrexed pre-treatment did not enhance the accumulation of intracellular NPe6.

**NPe6-PDT induced the expression of TS.** The inhibition of TS, resulting in a decrease in thymidine available for DNA synthesis, is reportedly the primary mechanism of pemetrexed (34,35). Therefore, we hypothesized that TS expression may affect the efficacy of combination therapy with pemetrexed and NPe6-PDT. We examined TS protein expression in the MPM cell lines using

---

Figure 3. Nude mice transplanted with MSTO-211H tumors measuring 5-7 mm in diameter were treated by pemetrexed and/or NPe6-PDT. The tumor volumes were calculated using the following formula: tumor volume = L^2D/2 (L, long diameter; D, short diameter). Untreated MSTO-211H tumors as control (●, N=10), treated by NPe6-PDT alone (●, N=10), treated by pemetrexed following by photodynamic therapy (PDT) (●, N=10), treated by PDT followed by pemetrexed (x, N=10), treated by pemetrexed alone (●, N=10). For the pemetrexed followed by PDT treatment (●), mice were intraperitoneally injected with pemetrexed (150 mg/kg daily) on days 7-11; on day 12, the mice were intravenously injected with NPe6 (10 mg/kg) and then irradiated with a 664-nm laser (100 J/cm^2) 2 h later. The laser spot size was 14 mm in diameter, and the power output at the fiber tip was 154 mW. The irradiation time was 16 min and 40 sec. For the PDT followed by pemetrexed treatment (x), mice were intravenously injected with NPe6 (10 mg/kg) and then 2 h later irradiated with a 664-nm laser (100 J/cm^2) on day 7; on days 8-12, the mice were intraperitoneally injected with pemetrexed (150 mg/kg daily). Tumor response was monitored until day 28, and the ratio of the tumor volume was calculated by comparing the volume with tumor volume on day 7.
an immunohistochemical analysis (Fig. 5). The expression of TS was relatively low in MSTO-211H and NCI-H2052 cells but was relatively high in NCI-H2452 and NCI-H28 cells (Fig. 4).

In the *in vivo* model, NPe6-PDT induced TS expression in the MSTO-211H tumors 24 h after the laser irradiation (Fig. 5). These results suggest that the overexpression of TS protein
induced by NPe6-PDT may be associated with the failure of pemetrexed to exert a tumoricidal action. Therefore, we concluded that NPe6-PDT followed by pemetrexed treatment did not enhance tumor cell lethality in the in vivo model.

Discussion

Recently, Debeuf et al reported that PDT affects vascular barrier function and thus increases vessel permeability; this phenomenon may be exploited to facilitate targeted drug delivery (36). Snyder et al also reported that a direct vascular effect of PDT at relatively low light doses may be exploited to increase the uptake of systemically circulating drugs to tumors, and this new treatment concept has been named ‘photodynamic drug delivery’ (37). They developed a novel PDT treatment that enhances the delivery and efficacy of macromolecule-based cancer therapy, such as a liposomally encapsulated formulation of doxorubicin (37). Low-dose PDT reportedly increases microvessel permeability, thereby promoting the controlled release of circulating drugs into tissues; PDT additionally stimulates leukocyte-endothelial cell interactions, mediating the effects of PDT on improved drug delivery (38). Therefore, we hypothesized that NPe6-PDT may enhance the delivery of pemetrexed to the tumors and suspected that NPe6-PDT followed by pemetrexed treatment could provide a synergistic or additive effect in vivo. However, NPe6-PDT followed by pemetrexed did not enhance tumor cell lethality, compared with NPe6-PDT alone, either in vitro (Fig. 2B) or in vivo (Fig. 3). These results indicated that NPe6-PDT could not enhance the antitumor activity of pemetrexed and in fact produced some resistance to treatment, compared with PDT alone.

Pemetrexed reportedly inhibits multiple enzymes in the folate metabolic pathway, with TS being the main target. In NSCLC cell lines, high baseline TS expression levels confer resistance to pemetrexed, and the TS level is correlated with pemetrexed efficacy in a variety of solid tumors. As shown in Fig. 5, the expression of TS was relatively low in MSTO-211 and H2052 cells, which were somewhat more sensitive to pemetrexed than the H2454 and H28 cells (as shown in Fig. 1A). Based on our data shown in Fig. 1A regarding the growth inhibitory effects of pemetrexed, the H2052 cells were the most sensitive to pemetrexed of all the cell lines examined, as in a previous report, because the TS level was relatively low in the H2052 cells, compared with in the H2454 and H28 cells (25). As shown in Fig. 6, NPe6-PDT at the IC_{50} dose induced the expression of TS in MSTO-211 cells. Therefore, based on these results, we concluded that NPe6-PDT followed by pemetrexed treatment did not enhance tumor cell lethality possibly because of the NPe6-PDT-induced expression of TS. Moreover, we previously reported that NPe6-PDT can damage the microvasculature around tumors and induce a vascular shut-down effect, decreasing blood flow to the tumors (17). Sitnik et al also reported that PDT-induced microvasculature damage is associated with a significant decrease in the blood flow and severe hypoxia in the tumor (39). We suggested that NPe6-PDT does not enhance the delivery of pemetrexed but may, in fact, obstruct the delivery of pemetrexed to tumors.

Oleinick et al reported that photosensitizer accumulation can influence cellular sensitivity to PDT (40). Robey et al reported that the expression of ATP-binding cassette (ABC) transport proteins, which render tumor cells resistant to chemotherapeutic drugs, decreases the accumulation of photosensitizers and causes resistance to PDT (41). We have also previously reported that BCRP, a member of the ABC transporter family, decreases the accumulation of Photofrin and may be a molecular determinant (29).

Anand et al reported that methotrexate (MTX) stimulated the accumulation of an intracellular photosensitizer, protoporphyrin IX, and enhanced the antitumor effect of PDT using 5-aminolaevulinic acid (ALA), but that ALA-PDT followed by MTX yielded no enhancement in tumor cell lethality (42,43). In the present study, as shown in Fig. 4, pemetrexed pre-treatment did not enhance the accumulation of intracellular NPe6. Further study is needed to explain why the combination of pemetrexed pre-treatment and NPe6-PDT has an additive effect on NPe6-PDT cytotoxicity both in vitro and in vivo. In conclusion, combination therapy using pemetrexed followed by NPe6 can enhance the cytotoxic effect of NPe6 and has important clinical implications.

Pass et al reported that intraoperative PDT did not prolong the survival of patients with MPM (22). However, we recently reported that NPe6-PDT exerted a strong antitumor effect against cancer lesions (29). Therefore, combination treatment using pemetrexed followed by NPe6-PDT may become a new

Figure 6. Immunohistochemical staining of MSTO-211H tumors. The MSTO-211H tumors in BALB/c nude mice were collected (A) before photodynamic therapy (PDT) and (B and C) 24 h after PDT. Immunohistochemical staining was performed using anti-TS antibody [magnification in (A) x10; (B) x10; (C) x40].
treatment modality, and further combination with surgery may reduce local recurrence and prolong the survival of patients with malignant mesothelioma.

Acknowledgements

This study was supported in part by a Grant-in-Aid for Scientific Research (C) from Japan Society for the Promotion of Science (JSPS) (to J.U.) (KAKENHI 21519826).

References


